Dimed: Q2 2025 delivered robust sales, margin, and market share growth, with strong digital and expansion momentum

About this update from Dimed S.a. Distribuidora De Medicamentos

Q2 2025 saw nearly 20% sales growth, strong EBITDA and net income gains, and continued market share expansion, driven by digital, private label, and store expansion strategies. Positive trends are expected to continue, with further margin improvements and growth in key categories.Based on This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

View stock analysis, news, and events for Dimed S.a. Distribuidora De Medicamentos